FibroBiologics to Present at the 2025 ThinkEquity Conference
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 2025 ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental, New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 2025 ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental, New York City. The company presentation is scheduled for 4:30 p.m. ET on October 30, and management will be available for one-on-one investor meetings throughout the event.
For presentation details or to request a meeting, contact the company via its website or email info@fibrobiologics.com.
Details
News Market Reaction – FBLG
On Oct 14, the day this news came out, FBLG closed 4.20% below the previous close.
Data tracked by StockTitan Argus for the Oct 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City.
FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.